SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001062993-22-010574
Filing Date
2022-04-20
Accepted
2022-04-20 18:22:04
Documents
1
Period of Report
2022-04-19

Document Format Files

Seq Description Document Type Size
1 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES form4.html 4  
1 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES form4.xml 4 6898
  Complete submission text file 0001062993-22-010574.txt   9867
Mailing Address 321 SUMMER STREET SUITE 400 BOSTON MA 02210
Business Address 321 SUMMER STREET SUITE 400 BOSTON MA 02210 857-330-4340
Inozyme Pharma, Inc. (Issuer) CIK: 0001693011 (see all company filings)

IRS No.: 475129768 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address 501 SECOND STREET, SUITE 200 SAN FRANCISCO CA 94107
Business Address 501 SECOND STREET, SUITE 200 SAN FRANCISCO CA 94107 (345) 949 1040
Pivotal bioVenture Partners Fund I, L.P. (Reporting) CIK: 0001695076 (see all company filings)

State of Incorp.: E9 | Fiscal Year End: 0331
Type: 4 | Act: 34 | File No.: 001-39397 | Film No.: 22839220

Mailing Address 501 SECOND STREET, SUITE 200 SAN FRANCISCO CA 94107
Business Address 501 SECOND STREET, SUITE 200 SAN FRANCISCO CA 94107 (415) 697-1002
Pivotal bioVenture Partners Fund I U.G.P., Ltd (Reporting) CIK: 0001752847 (see all company filings)

State of Incorp.: E9 | Fiscal Year End: 1231
Type: 4 | Act: 34 | File No.: 001-39397 | Film No.: 22839218

Mailing Address 501 SECOND STREET, SUITE 200 SAN FRANCISCO CA 94107
Business Address 501 SECOND STREET, SUITE 200 SAN FRANCISCO CA 94107 (415) 697-1002
Pivotal bioVenture Partners Fund I G.P., L.P. (Reporting) CIK: 0001752862 (see all company filings)

State of Incorp.: E9 | Fiscal Year End: 1231
Type: 4 | Act: 34 | File No.: 001-39397 | Film No.: 22839219